ADAM17 is one target of miR-122 and is implicated in numerous human diseases including cancer, heart disease, diabetes, rheumatoid arthritis, kidney fibrosis, Alzheimer’s disease, and it is a promising target for future treatments. This evidence concerns the gene ADAM17 and diabetes mellitus.